University of Massachusetts

Affinivax, Inc.

Medarex Inc.

Harvard College

University System of Maryland

E. R. Squibb Sons, Inc.

Teresa J Broering

Gregory Babcock

Donna Ambrosino

Richard Malley

William D Thomas, Jr

Israel Lowy

Robert F Graziano

Yingjie Lu

Fan Zhang

Robert Barry Mandell

Hector Javier Hernandez

Shite Sebastian

Deborah Molrine

Velupillai Puvanesarajah

Hui-Fen Zhang

George Rainer Siber

Zuoshang Xu

Gilles R Besin

Gang Yao

Taylor C Stevenson

Onkar Sharma

Janet E McCombs

William D Thomas

Gregory J Babcock

Francis Michon

Alan S Cross

Raphael Simon

Sharon Tennant

Susan Sloan

Naomi K Boatright

Colby Souders

Heidi Burke

Max L Nibert

Cathy Lea Miller

Robert Mandell

Alan Cross

Technologies for the prevention and/or treatment of pneumococcal infections.

Multivalent pneumococcal vaccines

Technologies for the prevention and/or treatment of nosocomial infections.

Immunogenic compositions

Aspects of the present disclosure relate to binding agents (e.g., antibodies and antigen binding fragments) that bind soluble fms-like tyrosine kinase 1 (sFlt1) in an isoform specific manner. In some embodiments, immunological assay methods utilizing isoform-specific antibodies or antigen binding fragments that bind sFlt1 isoforms are provided for assessing biological samples obtained from pregnant subjects, e.g., for purposes of evaluating preeclampsia status in the subject.

Isoform specific soluble FMS-like tyrosine kinase (sFlt) binding agents and uses thereof

The present invention features anti-SOD1 antibodies and methods of using the antibodies for the treatment of amyotrophic lateral sclerosis (ALS) or the amelioration of symptoms associated with ALS.

Anti-SOD1 antibodies and uses thereof

Antibodies that specifically bind to toxins of, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.

Antibodies against clostridium difficile toxins and uses thereof

The present invention provides methods and compositions for detecting protein-protein and/or protein-nucleic acid interactions in cells.

Method and composition for detecting protein-protein and protein-nucleic acid interactions

Isolated human monoclonal antibodies which bind to hepatitis C virus (HCV), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Human antibodies against hepatitis C virus (HCV) and uses thereof

[object Object]

Growing community of inventors

Brookline, MA, United States of America

Teresa J Broering